RGEN / Repligen: Life Sciences Tools' Best Near-Cap Gain Buy

Repligen (RGEN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earning more_horizontal

Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at more_horizontal

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology app more_horizontal

WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lea more_horizontal

Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Inv more_horizontal

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earning more_horizontal

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 mill more_horizontal

Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic more_horizontal